Ocular Therapeutix AXPAXLI Wet AMD Trial Hits Randomization Target, Topline Data in 1H 2027.

Ocular Therapeutix has achieved the randomization target of 555 subjects in its SOL-R registrational trial of AXPAXLI in wet age-related macular degeneration. The company will continue to enroll subjects currently in the loading phase, with topline data expected in the first half of 2027. This trial, along with SOL-1, will form the basis of a potential NDA submission for AXPAXLI in wet AMD.